thank quarter and joining for us Good earnings you call third XXXX and our afternoon for business update.
questions. on to Financial a update. of James upcoming data Joining Delfini, brief an update Officer. financial today this and answer trials my give are are us me and our colleagues, I Trevi's, will Chief X Trevi's Lisa Officer; Then Cassella, Dr. milestones any the on and happy Chief Development call Lisa will give
I take has you joined our First, to to Jim our as introduce like minute and would a team Officer. Cassella, recently Chief who Development leadership
in in Jim you Pharma As the role. Yale deep brings and inhibitor Pharmaceuticals of successful EVP, postdoctoral Alexza from was Ph.D. XXXX from and approval of wealth a in at X Development Medicine. for of Psychiatry School psychology to Board approval European U.S. to be and on as served Jim of neuroscience CNS in of in and Jim responsible the as NDA the has Concert Trevi where the for an Adasuve.
Jim regulatory background fellowship he the to with over Prior Department U.S. joining completed where therapies. drug late-stage advance a physiological of XXXX, CDO Concert, may and specifically Dartmouth some Phase me for Trevi, been working the approval years drug received Jim development on joining we the at resulting over a valuable our Prior XX that Research know, was and a College Jim out to CNS upcoming including time and development. experience Phase which the JAK months a and He experience, autoimmune for years XXXX, which trials III led has in read exciting has prepare past studies the recent been development pivotal Directors will to of submission. CSO Pharmaceuticals, invaluable important development joins we as at into activities, Trevi, III Sun Leqselvi. FDA by was acquired adviser he
been continued execute at productive Jim.
This against refractory plans quarter well our development a to cough pulmonary IPF, very or patients for with as as we fibrosis, with has as clinical Trevi RCC. welcome, patients So and idiopathic chronic cough or chronic both
in and on We readouts we we saw have strong cough. patients with of trial build chronic the a number upcoming in efficacy data to IPF Phase IIa hope our
conditions.
I on these we advanced seminal will creation in continued programs, will disease suffering products in I the of serious therapies development modification both being upcoming drugs them I reminding the data in for competitors' X need studied which of readouts, us in in RCC, from clinical our value through discuss As as for order company. continued have as our there timing. patients failures update IPF been an new trials well clinical for run in have believe are with the
so Potential studies Abuse you cared ever you and discussed than about know have study. or Human the extensively HAP investors HAP with I'm more up, First analysts, I to. feel you this all sure
we prepare the let HAP So me points key on summarize as for data.
unscheduled reminder, of at for by around indicated chemical on regularly a looks and not entity, and mechanism. drugs based scheduling DEA. has is decades As delivery nalbuphine, been DEA injectable the pain, the severe molecules The for which schedules the remained has
review, has of their date the kept XXXX, nalbuphine last as recently the unscheduled. As DEA
I to recent Importantly, you summarize their wanted for opinion. in their reasonings
are agonist which mu drugs. is or agonist class unscheduled All to that kappa mitigate either is were kappa KAMA, a and unique antagonist potential. a and is these antagonist are mechanism drugs antagonist mu abuse of a nalbuphine's Nalbuphine First the of designed in action. agonist mixed or
nalbuphine drug at precipitate mu, is its which to antagonistic due effects to attractive abusers withdrawal. potent less Second,
nalbuphine though even forensic is personnel cites nalbuphine for analysis. labs DEA enforcement the available, submitted Third, encountered that or currently to by is law rarely
of to with So is it and lot a nalbuphine as a DEA. not is the molecule history there new
why HAP at guidance that So drugs. all? FDA all HAP from There the is are XXXX we doing requires active for studies study CNS
day up bringing So we the are package current to standards.
has reviewed Finally, Substance only of is which of this in Controlled X-factor The part a X-factor study the as will FDA one HAP. group by the plan Staff, CSS, several plan. be the categories,
wait chronic unscheduled final we remain reasons but the see why approved a are So of nalbuphine to will in cough. if there will lot data, we believe
Okay.
indications. to on clinical Moving our
Next up for in data trial. cough IPF our will re-estimation be the sample size
scarce want years I been to for IPF the cough. have and XX X were antifibrotics antifibrotics significant chronic since have patients options approved note shown reduction First, that ago approved neither the in treatment of new
complaints potential data, Phase health tears risk been progression IPF have of transplant. patients, primary may Second, persistent role trials II there not cough of injury, increased respiratory as need such that cough a inflammation outcomes constant disease. mortality The by for we believe And other patients. in the be coughing lead or the one may these than our hospitalizations, by and caused third, lung for underlying micro to the any worse plays despite being a factor successful in
and is loved doctors. ones we to important our these continue to program patients, So their believe
parallel conduct study. Our to dose-ranging power the approximately external is will to a XX% in Phase by statistician IPF who The study is done patients sample size unblinded a an X-week company data. will that The in doses re-estimation, next and the arm CORAL Haduvio X actual trial placebo. using IIb XXX rerun patients. analysis the SSRE, when CORAL chronic is trial will active cough calculations analysis be the of milestone of the This complete study investigate
to or three, an power; drug within the of or but zone, the continue the prespecified working will which following patients We the not is the range and the drug planned one, with two, prespecified is should original informed consider be outcomes: will but in the the futility. require powering promising will assumptions; number get will back, working the maintain one company XXX of stopping very upsize the in information X limited on of patients, reconfirm
We have of the will expect December analysis we year. in we results which information, announce the this when of this
limit but anything trial aligned The answer N study, placebo-adjusted is the this to as is ultimate to for upper statistical a line data the the study the range, original change. ] the SSRE.
From full if continue first derisking back this both expect is the my XXXX, meaningful key outcome in top success the range in the SSRE of of clinically We half as for to event well perspective, [ of the subject futility. of the a
So it the size in right is this just a matter of population. figuring study out sample
treatment unmet continues despite data no approximately first a to adults in million an IIa quarter SSRE a and for of X that defined weeks exists.
With to RIVER approved our or new cough providers an condition mechanisms. condition lack in failures, X RCC therapies drug U.S. patients RCC. disease any for significant and underlying than Phase be where the urgency we need for U.S. from RCC candidate and IPF and XXXX there million persistent of Following underlying debilitating and the expect affects is X trial a greater as the cough, is for several in a lasting
many believe and RCC development, we are this mechanism the types and peripheral through failed why have that The peripheral-only failures is we been in we agents. The hypersensitivity cough Although central there our condition. our that unique have of are brain important drug linked in believe outcome. could change may have be drugs all many studying this in mechanism been
have the This XX signal coughs our unsuccessful. to now conducted per cough to last a is nalbuphine was if or programs to other with ER high randomized been been enrolled have cough the is XX per will by crossover at those stratified beginning or Phase trial the patient those and of be cough. IIa coughers equal with hour, a several cough on than ability approximately These population, patients patients. XX that we has shows trials placebo designed understand out with The to drug where conducted primary XXXX. trial coughs XX with greater total count, in RCC moderate analysis Our the these will to industry design across in were and but the patients enroll moderate fully hour,
cough are complete this to in excited QX chronic and XXXX. We condition of study significant report data for this the
Phase sample full with news these As financial we year, IIb followed completing the CORAL year-end turn in on results. well.
Then trials. see, expect progress lot of line no QX we of then summarize, top enrollment points.
I size. To looking in an assuming and CORAL top a Phase of in in XXXX, time eager all now it increase value exciting strong by in XXXX, from XXXX, to months you IIb to review are December first expect can as months, This data to Trevi our last SSRE at by RIVER data we made into the over data data this HAP over the representing will upcoming is each IIa inflection from Lisa few important the study line half and see the flow dosing the Phase
